drugset / Trial / NCT07156201

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

NCT07156201

Phase 1 Recruiting 74 enrolled Actio Biosciences, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.

Timeline

Start
2025-08-28
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ABS-1230 Unknown Oral
Background Omeprazole Other / unclassified

Indications

No indication recorded.